首页> 外国专利> USE OF ZC3H12B GENE OR PROTEIN AND ESTABLISHMENT METHOD FOR LIVER DISEASE ANIMAL MODEL

USE OF ZC3H12B GENE OR PROTEIN AND ESTABLISHMENT METHOD FOR LIVER DISEASE ANIMAL MODEL

机译:ZC3H12B基因或蛋白质的使用和肝病动物模型的建立方法

摘要

Use of a Zc3h12b gene or protein thereof and an establishment method for a liver disease animal model. By using a gene editing technology, the Zc3h12b gene of medaka is targeted and knocked out, and the medaka deleting the ZC3H12B protein product is established. All exhibits different degrees of liver diseases such as hepatobiliary hyperplasia and fusion, hepatocyte fatty degeneration, and fibrosis, exhibits significant fatty liver with the increase of months of age, local cyst necrosis, obvious lymphocyte infiltration in hepatic sinusoids, and abnormal increase in the number of macrophages. Furthermore, the cells in which human tumor markers CK19, SMA and GPC3 are positive are also detected, indicating that ZC3H12B can be used as a therapeutic target and biomarker for intrahepatic cystadenoma, intrahepatic cystadenocarcinoma, or fatty liver or liver cancer related thereto. Medaka deleting Zc3h12b can be used as an animal model to study the pathological process of intrahepatic cystadenoma, intrahepatic cystadenocarcinoma or both.
机译:ZC3H12B基因或其蛋白质及肝脏疾病动物模型的建立方法。通过使用基因编辑技术,Medaka的ZC3H12B基因是针对性和敲除的,并且建立了缺血的MedaKa缺失ZC3H12B蛋白质产物。所有这些都表现出不同程度的肝脏疾病,如肝胆增生和融合,肝细胞脂肪变性和纤维化,随着年龄的增长,局部囊肿坏死,肝脏鼻窦中明显淋巴细胞浸润以及数量异常增加,表现出显着的脂肪肝。巨噬细胞。此外,还发现了人肿瘤标志物CK19,SMA和GPC3的细胞也被检测到阳性,表明ZC3H12B可用作治疗靶标和生物标志物,用于肝内膀胱瘤瘤,肝内膀胱瘤或脂肪肝或肝癌。 Medaka删除ZC3H12B可用作动物模型,以研究肝内膀胱组瘤,肝内膀胱瘤细胞瘤或两者的病理过程。

著录项

  • 公开/公告号WO2021134842A1

    专利类型

  • 公开/公告日2021-07-08

    原文格式PDF

  • 申请/专利权人 SHANGHAI OCEAN UNIVERSITY;

    申请/专利号WO2020CN72609

  • 发明设计人 GUAN GUIJUN;CHANG YUYANG;

    申请日2020-01-17

  • 分类号A61K45;A61K38;A61P35;C12N15/85;

  • 国家 CN

  • 入库时间 2022-08-24 19:48:28

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号